Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase

Documenti analoghi

• The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients with Chronic Phase Chronic Myeloid Leukemia After Failure to Frontline Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?
  di: Cortes, Jorge, et al.
  Pubblicazione: (2011)
• Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
  di: Tam, Constantine S., et al.
  Pubblicazione: (2008)
• The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  di: Jabbour, Elias, et al.
  Pubblicazione: (2011)
• Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients with Refractory Hematologic Malignancies
  di: Badar, Talha, et al.
  Pubblicazione: (2015)
• Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
  di: Quintás-Cardama, Alfonso, et al.
  Pubblicazione: (2009)